Top

Published in:

01-08-2014 | Astute Clinician Report

SCIg vs IVIg: Let’s Give Patients the Choice!

Authors: K. Samaan, M. C. Levasseur, H. Decaluwe, C. St-Cyr, H. Chapdelaine, A. Des Roches, E. Haddad

Published in: Journal of Clinical Immunology | Issue 6/2014

Excerpt

Intravenous immunoglobulins (IVIg) and subcutaneous immunoglobulins (SCIg) are equally efficient in preventing serious bacterial infections (1‐5) in patients with primary immune deficiency (PID). Currently, SCIg or IVIG use is often based upon physician’s judgment (2, 6). However, in some centers such as ours, patients are given the choice of treatment modality, regardless of the physician’s opinion on “idealness” of the candidate. In this retrospective study of 143 patients with PID treated by immunoglobulin (Ig) replacement, we present our experience regarding patient’s behavior when given choice of hospital-based IVIg versus home-based SCIg. …

Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous Ig GSG. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26(3):265–73.PubMedCrossRef

Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11(6):532–8.PubMedCrossRef

Chapel HM, Spickett GP, Ericson D, Engl W, Eibls MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94–100.PubMedCrossRef

Ballow M. Immunoglobulin therapy: methods of delivery. The J of allergy and clin immunol. 2008;122(5):1038–9.CrossRef

Haddad E, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfusion and apheresis science : official j of the World Apher Assoc : official j of the Eur Soc for Haemapheresis. 2012;46(3):315–21.

Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32(6):1153–64.PubMedCrossRef

Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin N Am. 2008;28(4):737–64.CrossRef

Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29(3):173–84.PubMedCrossRef

Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the american academy of allergy, asthma and immunology. The J of allergy and clin immunol. 2006;117(4 Suppl):S525–53.CrossRef

10.

Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics : targets & ther. 2012;6:277–87.

11.

Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Bock A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. The J of allergy and clin immunol. 2004;114(4):936–42.CrossRef

12.

Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65–72.PubMedCrossRef

13.

Fasth A, Nystrom J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28(4):370–8.PubMedCrossRef

14.

Ducruet T, Levasseur MC, Des Roches A, Kafal A, Dicaire R, Haddad E. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. The J of allergy and clin immunol. 2013;131(2):585–7. e1-3.CrossRef

15.

Charles C, Gafni A, Whelan T. Decision-making in the physician ± patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med. 1999;49(5):651–61.PubMedCrossRef

16.

Stevensona FA, Barry CA, Brittenb N, Barberc N, Bradley CP. Doctor-patient communication about drugs: the evidence for shared decision making. Soc Sci Med. 2000;50(6):829–40.CrossRef

Title: SCIg vs IVIg: Let’s Give Patients the Choice!
Authors: K. Samaan
M. C. Levasseur
H. Decaluwe
C. St-Cyr
H. Chapdelaine
A. Des Roches
E. Haddad
Publication date: 01-08-2014
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 6/2014
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-014-0057-9

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

SCIg vs IVIg: Let’s Give Patients the Choice!

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2014

High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine

Clinical Heterogeneity of Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linked: Pulmonary Involvement as a Non-Classical Disease Manifestation

Erratum to: TH1/TH2 Functional Imbalance After Acute Myocardial Infarction: Coronary Arterial Inflammation or Myocardial Inflammation

Major Histocompatibility Complex Class II Deficiency Complicated by Mycobacterium avium Complex in a Boy of Mixed Ethnicity

Autologous Human Cytomegalovirus-Specific Cytotoxic T Cells as Rescue Therapy for Ulcerative Enteritis in Primary Immunodeficiency

Tetratricopeptide Repeat Domain 7A (TTC7A) Mutation in a Newborn with Multiple Intestinal Atresia and Combined Immunodeficiency

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page